Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.98 |
| ▸ | GFER | P55789 | 1/20 | 0.98 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | TSHR | P16473 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.60 |
| ▸ | AXL | P30530 | 1/20 | 0.60 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17073207 | 0.99 | ALDH1A1 (1.00) | ALDH1A1KDM4EUSP2HPGDNPSR1 | |
| SCHEMBL17073210 | 0.89 | ALDH1A1 (1.00) | ALDH1A1KDM4EUSP2HPGDNPSR1 | |
| SCHEMBL30058951 | 0.82 | ALDH1A1 (0.68) | ALDH1A1KDM4EUSP2HPGDNPSR1 | |
| SCHEMBL18590594 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KDM4EUSP2HPGDNPSR1 | |
| SCHEMBL28882091 | 0.80 | ALDH1A1 (0.69) | ALDH1A1KDM4EUSP2HPGDNPSR1 | |
| SCHEMBL7036372 | 0.79 | ALDH1A1 (0.66) | ALDH1A1KDM4EUSP2HPGDNPSR1 | |
| Bromide SCHEMBL6833451 | 0.78 | ALDH1A1 (0.65) | ALDH1A1KDM4EUSP2HPGDNPSR1 | |
| SCHEMBL6196239 | 0.78 | CYP19A1 (1.00) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL17073162 | 0.77 | ALDH1A1 (0.74) | ALDH1A1KDM4EUSP2HPGDNPSR1 | |
| SCHEMBL17073204 | 0.77 | KDM4E (1.00) | ALDH1A1KDM4EUSP2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020150423-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | YUMANITY THERAPEUTICS, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2020-07-16 | — | — | US | disclosed |
| US-20170066731-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | Sanford Burnham Prebys Medical Discovery Institute | 2017-03-09 | — | — | US | disclosed |
| US-20170066731-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | Sanford Burnham Prebys Medical Discovery Institute | 2017-03-09 | — | — | US | disclosed |
| WO-2015134790-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200222400-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | ALDH1A1 934/4885KDM4E 3693/4885USP2 2350/4885 |
| US-20170066731-A1 | SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS | FASN, FADS2, FADS1 | ALDH1A1 831/4885KDM4E 2331/4885USP2 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.